FDA Off-Label Hearing: Day One
Conclusion
While any policy changes will not be immediate, the public meeting shows that the FDA is interested in listening to stakeholders, allowing them face time to speak and meet with FDA officials. Any change – even a small change – has the power to influence what kind of information patients receive on drugs and devices, and industry and the FDA have a responsibility to ensure public health remains a priority.
Related StoriesFDA Open to Biomarker CommentsOpen Payments Having an Adverse Effect on Physician-Rep RelationshipsRepresentative Lieu Laser-Focused on Device Act, Olympus
Source: Policy and Medicine - Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs